VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease.

RATIONALE

Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing in the exon-8 of vascular endothelial growth factor (VEGF)-A results in production of proangiogenic VEGFa isoforms (VEGFa, 165 for the 165 amino acid product) and antiangiogenic VEGFb (VEGFb) isoforms.

OBJECTIVE

The antiangiogenic VEGFb isoforms are thought to antagonize VEGFa isoforms and decrease activation of VEGF receptor-2 (VEGFR2), hereunto considered the dominant receptor in postnatal angiogenesis in PAD. Our data will show that VEGFb inhibits VEGFR1 signal transducer and activator of transcription (STAT)-3 signaling to decrease angiogenesis in human and experimental PAD.

METHODS AND RESULTS

In human PAD versus control muscle biopsies, VEGFb: (1) is elevated, (2) is bound higher (versus VEGFa) to VEGFR1 not VEGFR2, and (3) levels correlated with decreased VEGFR1, not VEGFR2, activation. In experimental PAD, delivery of an isoform-specific monoclonal antibody to VEGFb versus control antibody enhanced perfusion in animal model of severe PAD (Balb/c strain) without activating VEGFR2 signaling but with increased VEGFR1 activation. Receptor pull-down experiments demonstrate that VEGFb inhibition versus control increased VEGFR1-STAT3 binding and STAT3 activation, independent of Janus-activated kinase-1)/Janus-activated kinase-2. Using VEGFR1 mice that could not increase VEGFR1 after ischemia, we confirm that VEGFb decreases VEGFR1-STAT3 signaling to decrease perfusion.

CONCLUSIONS

Our results indicate that VEGFb prevents activation of VEGFR1-STAT3 signaling by VEGFa and hence inhibits angiogenesis and perfusion recovery in PAD muscle.